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Case Report
A 53-year-old Italian man presented to the emer-
gency department with worsening dyspnea on exertion
for about 18 months, without further symptoms like
chest pain or syncope. For those symptoms he recently
decided to undergo a pneumological examination in-
cluding lung function test, that resulted normal. 
He had history of recent pneumonia, systemic ar-
terial hypertension treated with ACE inhibitors, de-
pressive anxious syndrome, and one episode of acute
urinary retention associated with benign prostatic hy-
perplasia chronically treated with alfuzosin.
In the Emergency Department the patient was ori-
ented and presented a Kelly Score 1, he was apyretic,
his arterial pressure was 150/95 mmHg, the cardiac
rate was 105 beats per minute, SpO2 was 93% in am-
bient air with a respiratory rate of 22 breaths per
minute. Physical examination showed neither alter-
ation, apart from tachycardia, nor signs of depth or su-
perficial venous thrombosis (DVT, SVT). Previous
and family medical history did not include any
episodes of thromboembolism nor events that could
lead to that disease (traumatic events, surgical proce-
dures, long bed resting). Wells score calculation re-
sulted in an intermediate probability of PE (4.5 pts).
A differential diagnosis process for dyspnea was exe-
cuted: EKG showed sinus rhythm, 100 beats per
minute, S1Q3T3 and right ventricular volume over-
load signs, arterial blood gas analysis resulted in type
1 respiratory failure and respiratory alkalosis, while
chest x-ray showed bilateral increased volume of pul-
monary hila and vascular structures in the superior
pulmonary area (Figure 1). Laboratory tests showed
high D-dimer 3740 ng/mL (reference values 0-500
ng/mL), troponin 32 ng/L (reference values <34 ng/L).
A computed tomography angiography (CTA) con-
firmed PE affecting the main branches of the pul-
monary arteries and the lobar and segmental branches
of the lower lobes (Figure 2). 
Once hospitalized in sub-intensive care unit a bed-
side ultrasound study was immediately performed,
showing a negative compression ultrasonography, a
left lung focal interstitial syndrome and a right cardiac
dilation with tricuspid annular plane systolic excursion
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ABSTRACT
Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially fatal complication of pulmonary embolism
(PE). Organized thrombus in the pulmonary artery causes a chronic obstruction, leading to a vascular system remodeling, an
increase of pulmonary vascular resistance and a chronic pulmonary hypertension. Epidemiology is mostly unknown due to the
difficult diagnostic process that often leads to a late diagnosis: findings of persistent pulmonary hypertension (PH), despite
correct treatment of PE, lead to the diagnostic suspect. The first choice treatment is pulmonary endarterectomy (PEA) associated
with lifelong anticoagulant therapy with vitamin K antagonist. We present the case of a 53-year-old male affected by dyspnea
for months, admitted to a sub-intensive care unit for intermediate low-risk PE; echocardiography showed signs of PH persisting
after anticoagulant therapy; after 2 months of specific treatment the diagnosis of CTEPH was confirmed and the patient was
successfully treated with PEA.
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(TAPSE) of 12 mm (reference values >16 mm), left
ventricular D-shape with 55% ejection fraction (ref-
erence values 50-70%), and a systolic pulmonary ar-
tery pressure (sPAP) of 80 mmHg (reference values
18-25 mmHg).
Prognostic risk stratification resulted in an inter-
mediate low class risk (sPESI 0 with the presence of
right ventricular dysfunction) and anticoagulant ther-
apy with weight-adjusted low molecular weight he-
parin (LMWH) was administered (enoxaparin 8000
Figure 1. Chest radiography: dilation of pulmonary artery, right hearth dilation.
Figure 2. Computed tomographic scan: thrombus inside left main pulmonary artery.
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IU twice daily for a 75 kg weight patient). During the
hospital stay, possible causes of PE were researched:
total body CT scan, tumor markers and thrombophilia
screening resulted all negative.
We discharged the patient with no symptoms, in-
dication to continue anticoagulant therapy with
LMWH, and with a diagnostic-therapeutic program
for pulmonary hypertension: right heart catheteriza-
tion (RCH) and pulmonary angiography as suggested
by the cardiology specialist.
The RCH was executed few days after discharge,
showing a mean pulmonary arterial pressure (mPAP)
of 47 mmHg (reference values 12-16 mmHg) and a
pulmonary capillary wedge pressure (PCWP) of 9
mmHg (reference values 6-12 mmHg), meaning a se-
vere pre-capillary PH and a severe reduction of car-
diac performance. A pulmonary angiography was
executed as well, revealing a thromboembolic in-
volvement of all pulmonary principal arterial
branches: cardiology specialist suspended LMWH and
administered dabigatran 150 mg twice daily and maci-
tentan 10 mg daily.
Given the insufficient response to the pharmaco-
logical therapy, the patient was rehospitalized in a spe-
cialized center (Policlinico Sant’Orsola-Malpighi of
Bologna) for new evaluation with trans-thoracic
echocardiography, lung function tests, RHC, pul-
monary angiography and coronary angiography: all
these tests showed an impaired cardiac index (NYHA
III class) and for these reasons sildenafil was added to
the existing therapy.
After 2 months of correctly administered therapy
symptoms persisted: this led to the definitive diagno-
sis of CTEPH. The patient was treated with PEA (Fig-
ure 3) during extracorporeal circulation, deep
hypothermia and selective cerebral anterior perfusion.
Subsequent ultrasound study showed a major reduc-
tion of right ventricular pressure and of indirect signs
of PH (sPAP of 25 mmHg), an improvement of right
ventricular function (TAPSE 16 mm). The patient was
finally discharged with indication of anticoagulant
therapy with Warfarin adjusted to international nor-
malized ratio (INR) range of 2-3 indefinitely.
Discussion
CTEPH is a complication of PE: it may develop as
a consequence of misdiagnosed and untreated PE, but
also after a correctly treated PE.1 Overall incidence in
unknown since many bias interfere with a correct sta-
tistical calculation (e.g. misdiagnosed and asympto-
Figure 3. Surgical finding.
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matic CTEPH); an estimate shows 1 to 5% of surviv-
ing PE patients with average age of 63 and no sex dif-
ferences in prevalence.2
Etiology is unclear, but many risk factors have
been identified in the genesis of CTEPH: history of
PE or DVT, ventriculoatrial shunt, implantable car-
dioverter defibrillator or pacemaker infection, splenec-
tomied patient, coagulation pathologies (e.g. high
blood levels of factor VIII or antiphospholipid anti-
body syndrome), non-0 blood type, hormone-treated
hypothyroidism, malignancy, myeloproliferative dis-
ease, chronic osteomyelitis, and benign prostatic hy-
perplasia. 
Patients with CTEPH can present various patho-
logic findings leading to the diagnosis: arterial throm-
bosis of the main pulmonary artery, ultrasound signs
of PH (e.g. right ventricular dysfunction), CT angiog-
raphy showing signs of chronic thromboembolism.
CTEPH usually results from a fibrotic evolution
of thrombus inside pulmonary artery with a mechani-
cal obstruction causing an incremental blood flow in
the remaining healthy arterial vessels, this leads to a
microvascular remodeling and progressive increase of
pulmonary vascular resistance.
Clinical presentation includes worsening dyspnea
and asthenia, until the severe PH and right ventricular
dysfunction bring more severe symptoms: chest pain,
syncope, abdominal pain (caused by hepatic conges-
tion).
Imaging is not defining for the diagnosis: plain
chest radiography can show dilation of pulmonary ar-
tery and, with the increase of PH, right hearth dilation,
CT scan results can be suggestive of PH showing a
main pulmonary artery/ascending aorta ratio >1.3
Average timing for diagnosis is about 2 year after
CTEPH insurgence. In the presence of clinical suspi-
cion, the first imaging test should be pulmonary
scintigraphy that is more sensible compared to CT an-
giography, followed by RHC and a pulmonary angiog-
raphy. Diagnostic criteria are the coexistence of PH
with RHC showing mPAP ≥25 mmHg and PCWP ≤15
mmHg and of pulmonary arterial thromboembolic oc-
clusion (established or alleged cause of PH).4
Primary differential diagnosis is with post-PE syn-
drome, a frequent occurrence in patient with treated
PE, characterized by persistence of PE symptoms and
limitations that cannot be explained by organic anom-
alies.5 Other possible differential diagnoses are cardi-
ologic, pulmonary and hematologic causes of chronic
dyspnea.
Surgery is the only definitive therapy: Pulmonary
EndArterectomy (PEA) can be executed after consid-
ering the surgical accessibility of the thrombi, the
presence of hemodynamic and/or ventilator impair-
ment and the impact of patients comorbidities on the
risk assessment for surgery.6 Balloon Pulmonary An-
gioplasty (BPA) represents another therapeutic option,
while the only medical treatment approved is riociguat
(stimulator of soluble guanylate cyclase); both BPA
and riociguat are intended for patients with inoperable
CTEPH or with persisting PH after PEA.
3-year survival after PEA is about 89% while it de-
creases to 70% in patients with inoperable CTEPH.7
Lifelong anticoagulant therapy with VKAs is rec-
ommended in all patients, there are no literature data
about DOACs efficiency. Diagnostic and treatment
procedures should be an exclusive of expert centers.
Conclusions
CTEPH is often a misdiagnosed complication of
PE. It has good prognosis if managed by specialized
centers and if surgically attackable, while the 3-year
survival ratio drops if the patient cannot undergo sur-
gery. Clinical suspicion should arouse when treating
a patient with dyspnea and history of PE or with signs
of PH not diagnosed before. 
Given the low overall incidence among the general
population and the severity of CTEPH, it is recom-
mended to leave the management to specialized and
expert centers. 
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